Luspatercept
Drug
Celgene Corporation
Total Payments
$5.7M
Transactions
560
Doctors
103
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $2.5M | 346 | 87 |
| 2018 | $2.0M | 180 | 34 |
| 2017 | $1.3M | 34 | 10 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.2M | 126 | 90.6% |
| Consulting Fee | $470,229 | 111 | 8.2% |
| Travel and Lodging | $50,547 | 170 | 0.9% |
| Food and Beverage | $14,398 | 147 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,900 | 5 | 0.1% |
| Education | $8.69 | 1 | 0.0% |
Payments by Type
Research
$5.2M
126 transactions
General
$542,083
434 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001) | Celgene Corporation | $721,806 | 0 |
| ACE-536-MDS-001 | Celgene Corporation | $714,240 | 1 |
| ACE-536-MDS-001 - A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) | Celgene Corporation | $631,356 | 9 |
| ACE-536-B-THAL-001 | Celgene Corporation | $597,819 | 0 |
| ACE-536-B-THAL-001 - A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia | Celgene Corporation | $586,357 | 4 |
| A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia (ACE-536-B-THAL-001) | Celgene Corporation | $524,918 | 4 |
| AAAR6967 - S1904 Luspatercept | Celgene Corporation | $373,584 | 0 |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) | Celgene Corporation | $341,672 | 11 |
| ACE-536-MF-001 - A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence | Celgene Corporation | $340,933 | 2 |
| A Phase 2, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Adults With Non-Transfusion Dependent Beta (?)-Thalassemia (The BEYOND Study) (ACE-536-B-THAL-002) | Celgene Corporation | $219,793 | 0 |
| A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions (ACE-536-MDS-002) | Celgene Corporation | $109,150 | 0 |
| ACE-536-B-THAL-002 - A Phase 2, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Adults With Non-Transfusion Dependent Beta (? | Celgene Corporation | $42,310 | 0 |
| ACE-536-MF-001 | Celgene Corporation | $2,783 | 4 |
Top Doctors Receiving Payments for Luspatercept
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New Orleans, LA | $5.1M | 90 |
| , MD | Internal Medicine | Bronx, NY | $51,195 | 11 |
| Sujit Sheth | Pediatric Hematology-Oncology | New York, NY | $30,556 | 16 |
| , MD | Pediatric Hematology-Oncology | Los Angeles, CA | $24,000 | 16 |
| , MD | Pediatric Hematology-Oncology | Chicago, IL | $19,017 | 12 |
| , M.D | Pediatrics | Philadelphia, PA | $18,266 | 13 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $17,961 | 9 |
| , MD | Hematology | Tampa, FL | $17,276 | 12 |
| , M.D | Hematology | Cincinnati, OH | $16,975 | 10 |
| , M.D | Pediatric Hematology-Oncology | San Diego, CA | $16,795 | 15 |
| , MD | Hematology & Oncology | Cleveland, OH | $16,713 | 8 |
| , M.D | Medical Oncology | Houston, TX | $14,738 | 6 |
| Amer Zeidan | Hematology & Oncology | New Haven, CT | $13,657 | 9 |
| , MD | Pediatric Hematology-Oncology | Memphis, TN | $13,247 | 8 |
| , M.D | Pediatric Hematology-Oncology | Oakland, CA | $12,694 | 10 |
| , M.D | Hematology & Oncology | Chagrin Falls, OH | $12,058 | 9 |
| , M.D | Hematology | Chicago, IL | $11,782 | 9 |
| , M.D | Pediatrics | Philadelphia, PA | $11,218 | 9 |
| , MD | Pediatric Hematology-Oncology | Cincinnati, OH | $11,042 | 6 |
| Bart Scott | Medical Oncology | Seattle, WA | $10,937 | 8 |
| , MD | Pediatric Hematology-Oncology | Dallas, TX | $10,470 | 8 |
| , M.D | Pediatrics | Philadelphia, PA | $10,343 | 8 |
| , M.D | Hematology & Oncology | New York, NY | $10,114 | 7 |
| , MD | Internal Medicine | Royal Oak, MI | $9,839 | 8 |
| , M.D | Hematology & Oncology | Boston, MA | $9,517 | 7 |
Ad
Manufacturing Companies
- Celgene Corporation $5.7M
Product Information
- Type Drug
- Total Payments $5.7M
- Total Doctors 103
- Transactions 560
About Luspatercept
Luspatercept is a drug associated with $5.7M in payments to 103 healthcare providers, recorded across 560 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $2.5M was paid across 346 transactions to 87 doctors.
The most common payment nature for Luspatercept is "Unspecified" ($5.2M, 90.6% of total).
Luspatercept is associated with 13 research studies, including "A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001)" ($721,806).